Comparative Pharmacology
Head-to-head clinical analysis: ROXICODONE versus RYZOLT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ROXICODONE versus RYZOLT.
ROXICODONE vs RYZOLT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxycodone is a full opioid agonist with high affinity for mu-opioid receptors, also binding to kappa and delta receptors. It acts primarily on the central nervous system and gastrointestinal tract.
RYZOLT is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, increasing serotonin levels in the synaptic cleft.
5-15 mg orally every 4-6 hours as needed for pain; immediate-release formulation. Maximum 60 mg total daily dose for opioid-naive patients.
10 mg orally once daily
None Documented
None Documented
3.5-5 hours for immediate-release; 4.5-5.5 hours for extended-release. Accumulation may occur with repeated dosing, especially in elderly or hepatic impairment.
Terminal elimination half-life is 12–15 hours in healthy adults; extended to 22–28 hours in patients with severe hepatic impairment.
Renal excretion: 70-80% as unchanged drug and metabolites (oxymorphone, noroxycodone); fecal: 10-20%.
Primarily hepatic metabolism with renal excretion of metabolites; renal elimination of unchanged drug <5%; biliary excretion accounts for ~10% of total clearance.
Category C
Category C
Opioid Analgesic
Opioid Analgesic